for orders over $200
MK 2866, also known as ostarine, is a selective androgen receptor modulator (SARM). It works by selectively binding to androgens receptors in the muscles and bones. Unlike steroids, it has a targeted approach and only displays anabolic function. It was first developed by pharmaceutical company GTx, Inc., for the treatment of osteoporosis and muscular dystrophy.
World anti-doping agency (WADA) has banned its use in sports because of its potential to enhance athletic performance. Research shows that ostarine might have cardioprotective effects and benefit diabetic patients. It is an investigational drug and MK- 2866 ostarine for sale is exclusively available for research purposes.
IUPAC Name:(2S)-3-(4-cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamideSynonym: ENOBOSARM, Ostarine, 841205-47-8, GTx-024Molecular Formula: C19H14F3N3O3Molecular Weight: 389.3 g/molCAS Number: 841205-47-8PubChem CID: 11326715
Strong evidence suggests that ostarine has a positive effect on muscle growth. Muscle function and physical performance decline with hormonal change in postmenopausal women. One study in ovariectomized rats found that ostarine treatment for five weeks resulted in increased capillary density in the gastrocnemius and longissimus muscles as compared to untreated rats, indicative of improved muscle tissue .
Similarly, one study in humans looked at the effects of ostarine on postmenopausal women and elderly men. Participants were randomized to receive 0.1, 0.3, 1 mg, 3 mg ostarine or placebo for three months. The results found increased lean body mass in a dose-dependent manner, with an increase of 1.4 kg at a 3mg dose, as compared to placebo. Further, treated patients exhibited improvement in the stair climbing test, indicative of physical performance, in terms of both speed and power .
The effect of ostarine on cachexia has been extensively studied in cancer patients. Cachexia is characterized by loss of skeletal muscle and reduced physical activity. In a randomized controlled double-blind phase 2 trial, non-obese postmenopausal women and elderly men with cancer, who had reported 2% weight loss, were enrolled. Participants either received ostarine (1mg, 3mg) or placebo for 113 days. Researchers found that patients who took ostarine experienced a significant increase in lean body mass .
Ostarine has been shown to improve bone mineral density and bone healing. One study in a rat model of osteoporosis found that ostarine treatment for five weeks improved structural properties such as bone mineral density and bone volume density .
Similarly, one study was conducted to check the effect of MK 2866 on bone healing in a ovariectomized rats. Some subjects received ostarine treatment at a dose of 0.04, 0.4, or 4 mg/kg. The researchers found that ostarine treatment positively affected bone healing, enhanced callus formation and callus density .
Data from phase 2 clinical trials show that ostarine has a beneficial effect on type 2 diabetes. The researchers noticed that ostarine treatment improved insulin resistance in elderly and postmenopausal women. It further revealed that ostarine 3mg administration led to an 11% decline in fasting blood glucose and a 26.8% reduction in insulin resistance.
This effect was more pronounced in prediabetic patients for whom the fasting blood glucose was reduced by 17% and insulin resistance decreased by 43.1%. Further, it caused a decrease in total body fat mass, which is a significant contributing factor to lowering insulin resistance .
The luminal androgen receptor is a type of triple‐negative breast cancer (TNBC) with the overexpression of androgen receptor (AR). Research shows that ostarine might be useful in AR+ breast cancer.
A phase 2 study looked at the effect of enobosarm and pembrolizumab combination in AR+ metastatic TNBC. The result found a modest clinical benefit of 25% at week 16 with well-tolerated side effects. However, the trial was stopped early due to the withdrawal of enobosarm .
Ostarine is a selective androgen receptor modulator that has been studied for its effect on muscle function and bone density. Currently, phase three trials are ongoing to study the safety and efficacy of ostarine in combination with abemaciclib for the treatment of ER+HER2- Metastatic Breast Cancer. It’s an investigational drug and the FDA has approved osatrine MK 2866 purchase for experimental purposes. At Element Sarms, the option to purchase MK-2866 is restricted to research and educational purchases. Only buy MK 2866 ostarine if you are a qualified researcher.
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind.
The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.